Protein enabled homolog (502-510)

Protein enabled homolog (502-510) is a synthetic peptide fragment corresponding to amino acids 502 to 510 of the protein enabled homolog, a member of the Ena/VASP family known for its critical role in regulating actin cytoskeleton dynamics. As a short, sequence-defined peptide, this fragment serves as a valuable molecular tool for dissecting protein-protein interactions, mapping functional domains, and studying the biochemical activities associated with the enabled homolog in various cellular contexts. Its defined sequence enables precise experimental manipulation, making it highly relevant for researchers investigating cytoskeletal organization, cell motility, and related signal transduction pathways.

Peptide-protein interaction studies: Researchers utilize this peptide fragment to probe specific binding interactions between the enabled homolog and its molecular partners. By incorporating the 502-510 sequence into assays such as surface plasmon resonance, pull-downs, or co-immunoprecipitation, scientists can identify and characterize binding affinities, elucidate interaction motifs, and map contact sites. This application supports the dissection of signaling networks that control actin assembly and cellular architecture, providing mechanistic insights into how Ena/VASP proteins coordinate with other regulatory factors.

Epitope mapping: The defined sequence of the 502-510 peptide enables its use as a reference epitope in antibody validation and mapping studies. By employing the fragment in immunoassays, investigators can determine antibody specificity, distinguish between closely related protein isoforms, and facilitate the development of sequence-specific reagents. This approach is particularly valuable in generating monoclonal or polyclonal antibodies targeting the enabled homolog, which are essential for downstream applications in immunodetection and localization experiments.

Peptide-based inhibitor screening: The 502-510 region represents a functionally significant motif within the enabled homolog, making the synthetic peptide a suitable candidate for competitive inhibition assays. By introducing this fragment into in vitro systems, researchers can assess its capacity to disrupt endogenous protein-protein interactions or modulate actin polymerization dynamics. Such studies are instrumental in screening for small molecules or other peptides that mimic or block enabled homolog function, supporting the discovery of novel modulators of cytoskeletal regulation.

Structural and conformational analysis: The peptide provides a tractable model for investigating local secondary structure and conformational properties pertinent to the enabled homolog. Through techniques such as circular dichroism spectroscopy, NMR, or X-ray crystallography, scientists can analyze the folding tendencies and structural motifs of the 502-510 segment. These studies contribute to a deeper understanding of how specific sequence elements influence the overall architecture and interaction capabilities of Ena/VASP proteins.

Peptide conjugation and functionalization: The 502-510 peptide serves as a versatile scaffold for chemical modification, labeling, or conjugation to other biomolecules. By attaching fluorescent tags, affinity handles, or cross-linkers, researchers can generate customized probes for advanced imaging, affinity purification, or proximity labeling experiments. This application expands the functional utility of the peptide, enabling high-resolution studies of subcellular localization, dynamic protein complexes, and the spatial organization of actin-regulatory networks.

1. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

3. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

4. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

5. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics